Morgan Stanley Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Key Points

• Morgan Stanley raised its price target on Regeneron from $769 to $796 while maintaining an "equal weight" rating, implying roughly a 6.36% upside from the current share price.
• Analysts collectively rate REGN a Moderate Buy with an average target of $811.96, and several firms (e.g., JPMorgan, Guggenheim, Piper Sandler) have set higher targets in the $875–$975 range.
• Regeneron delivered an earnings beat (EPS $11.44 vs. $10.74) and revenue above estimates, yet the stock traded down about 2.5% to $748.42, within a 12‑month range of $476.49–$821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective upped by investment analysts at Morgan Stanley from $769.00 to $796.00 in a research note issued on Friday,Benzinga reports. The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective suggests a potential upside of 6.36% from the stock's current price.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Piper Sandler began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an "overweight" rating and a $875.00 price objective on the stock. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a report on Monday, February 9th. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a report on Monday, February 2nd. Finally, Zacks Research downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $811.96.

Regeneron Pharmaceuticals Trading Down 2.5%

NASDAQ:REGN traded down $19.43 on Friday, reaching $748.42. The company's stock had a trading volume of 189,433 shares, compared to its average volume of 736,577. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market cap of $79.12 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 2.05 and a beta of 0.40. The stock has a 50 day moving average price of $767.27 and a 200 day moving average price of $717.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $12.07 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,774 shares of company stock worth $2,942,738. 7.02% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Regeneron Pharmaceuticals during the first quarter worth about $226,000. Arrowstreet Capital Limited Partnership acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $3,183,000. Gabelli Funds LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company's stock worth $978,000 after purchasing an additional 55 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $710,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.